INCYTE CORPORATION Induced Conversion of Convertible Debt Expense
INCYTE CORPORATION (INCY) reported Induced Conversion of Convertible Debt Expense of $54.88 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2020-02-13
- INCYTE CORPORATION induced conversion of convertible debt expense for the quarter ending 2017-12-31 was $0.00.
- INCYTE CORPORATION induced conversion of convertible debt expense for the quarter ending 2017-09-30 was $0.00.
- INCYTE CORPORATION induced conversion of convertible debt expense for the quarter ending 2017-06-30 was $751.00K.
- INCYTE CORPORATION induced conversion of convertible debt expense for the quarter ending 2017-03-31 was $54.13M.
- INCYTE CORPORATION induced conversion of convertible debt expense for fiscal 2017 was $54.88M.
- INCYTE CORPORATION induced conversion of convertible debt expense for fiscal 2014 was $265.00K, a 97.69% decline from fiscal 2013.
- INCYTE CORPORATION induced conversion of convertible debt expense for fiscal 2013 was $11.48M.
| Period end | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month | Induced Conversion of Convertible Debt Expense 9 month | Induced Conversion of Convertible Debt Expense 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $751.00K derived: sum of 3 quarters · filed 2020-02-13 | $54.88M 10-K · filed 2020-02-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $751.00K derived: sum of 2 quarters · filed 2018-10-30 | $54.88M 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $751.00K 10-Q · filed 2018-07-31 | $54.88M 10-Q · filed 2018-07-31 | ||
| 2017-03-31 | $54.13M 10-Q · filed 2018-05-01 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $0.00 derived: sum of 2 quarters · filed 2017-02-14 | $0.00 derived: sum of 3 quarters · filed 2017-02-14 | $265.00K 10-K · filed 2017-02-14 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $0.00 derived: sum of 2 quarters · filed 2015-11-03 | $265.00K 10-Q · filed 2015-11-03 | $487.00K derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $265.00K 10-Q · filed 2015-08-04 | $487.00K derived: sum of 3 quarters · filed 2016-02-12 | $1.98M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $265.00K 10-Q · filed 2015-04-30 | $487.00K derived: sum of 2 quarters · filed 2016-02-12 | $1.98M derived: sum of 3 quarters · filed 2016-02-12 | $11.75M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.71M derived: sum of 2 quarters · filed 2016-02-12 | $11.48M derived: sum of 3 quarters · filed 2016-02-12 | $11.48M 10-K · filed 2016-02-12 |
| 2013-09-30 | $1.49M 10-Q · filed 2014-10-30 | $11.26M derived: sum of 2 quarters · filed 2014-10-30 | $11.26M 10-Q · filed 2014-10-30 | |
| 2013-06-30 | $9.77M 10-Q · filed 2014-07-31 | $9.77M 10-Q · filed 2014-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |